BIRSA 101 – India's First Indigenous CRISPR-Based Gene Therapy for Sickle Cell Disease

India achieved an important milestone in genomic medicine on 19 November 2025 with the launch of BIRSA 101, described by the Government of India as the country's first indigenous CRISPR-based gene therapy for Sickle Cell Disease (SCD).

The breakthrough was developed at the:

CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB)

and was formally launched by:

Dr. Jitendra Singh

Union Minister of State (Independent Charge) for Science & Technology.

BIRSA 101 is based on an indigenous gene-editing platform and represents India's effort to develop advanced genetic therapies that can eventually be made more affordable and accessible than extremely expensive gene therapies available internationally.

The therapy has been named in honour of:

Bhagwan Birsa Munda

the iconic tribal freedom fighter and leader.

The name has particular significance because Sickle Cell Disease disproportionately affects several tribal populations in India.

For competitive examinations, remember the basic sequence:

BIRSA 101 → Sickle Cell Disease → CRISPR Gene Editing → CSIR-IGIB → Serum Institute → Birsa Munda → 19 November 2025

What Is BIRSA 101?

BIRSA 101 is an:

indigenously developed CRISPR-based gene-editing therapeutic programme for Sickle Cell Disease.

It represents an attempt to address the disease at its genetic basis rather than merely treating its symptoms.

This is fundamentally different from conventional supportive treatment.

Traditional management of Sickle Cell Disease may involve measures aimed at:

• controlling pain,

• preventing infections,

• managing anaemia,

• reducing complications and

• preventing organ damage.

Gene-editing approaches attempt to produce a more fundamental therapeutic effect by modifying relevant genetic or cellular pathways.

Who Developed BIRSA 101?

BIRSA 101 was developed at:

CSIR-Institute of Genomics and Integrative Biology

abbreviated:

CSIR-IGIB.

CSIR-IGIB is a constituent laboratory of:

Council of Scientific and Industrial Research (CSIR).

It is based in:

Delhi.

The institute conducts research in areas including:

• genomics,

• genome editing,

• rare genetic disorders,

• precision medicine,

• population genomics,

• molecular diagnostics and

• translational biomedical research.

Indigenous CRISPR Platform

A particularly important scientific fact is that BIRSA 101 is based on India's indigenous:

engineered FnCas9 CRISPR platform

also referred to in official material as:

enFnCas9.

This makes the development more significant than simply applying an imported CRISPR technology.

The underlying gene-editing platform itself has been developed through Indian research.

What Is FnCas9?

Cas9 proteins are enzymes used in CRISPR gene-editing systems.

The platform associated with BIRSA 101 uses an engineered form of:

FnCas9

derived from the Cas9 system associated with:

Francisella novicida.

The engineered system is designed for highly specific genome-editing applications.

For examination purposes, the most important distinction is:

BIRSA 101 → Indigenous engineered FnCas9 platform

rather than assuming that every CRISPR therapy uses exactly the same Cas9 system.

Technology Transfer to Serum Institute of India

An important part of the 19 November 2025 development was a formal:

Technology Transfer and Collaboration Agreement

between:

CSIR-IGIB

and:

Serum Institute of India Pvt. Ltd.

The objective is to translate the laboratory-developed technology into:

• scalable development,

• clinical translation,

• regulatory advancement,

• manufacturing and

• eventual commercialisation.

This is important because developing a successful laboratory technology and making a therapy available to patients are two very different stages.

Important Caution – Launch Does Not Mean Immediate Routine Treatment

Students should understand this carefully.

The announcement of BIRSA 101 as India's first indigenous CRISPR-based gene therapy does not mean that every Sickle Cell Disease patient could immediately receive it as a routinely available treatment from 19 November 2025.

Advanced gene therapies must pass through stringent processes involving:

Preclinical Development → Clinical Evaluation → Safety Assessment → Efficacy Assessment → Regulatory Review → Manufacturing Scale-Up → Approved Clinical Deployment

Official 2026 material describes the technology as licensed to Serum Institute for:

further development, regulatory advancement, manufacturing and commercialisation.

Therefore, the safest formulation is:

BIRSA 101 represents India's first indigenous CRISPR-based gene-editing therapy/platform for Sickle Cell Disease undergoing translation towards scalable clinical use.

Why Is It Called BIRSA 101?

The therapy was named:

BIRSA

in honour of:

Bhagwan Birsa Munda.

Birsa Munda was a major tribal leader and freedom fighter who resisted colonial rule.

He was born on:

15 November 1875.

The year 2025 marked his:

150th birth anniversary.

BIRSA 101 was launched only a few days after the anniversary.

Why Is Birsa Munda Connected With Sickle Cell Disease?

The connection is not biological but:

social, historical and public-health related.

Sickle Cell Disease disproportionately affects several tribal communities in India, particularly across parts of central, western and eastern India.

Naming the indigenous therapy after Birsa Munda therefore symbolically connects:

Advanced Genomic Science

with:

Tribal Health and Welfare.

Who Was Birsa Munda?

Birsa Munda was born on:

15 November 1875

in present-day Jharkhand.

He emerged as an influential tribal leader during British rule.

His movement is closely associated with:

Ulgulan

meaning broadly:

The Great Tumult/Rebellion.

He mobilised tribal communities against exploitation and colonial structures.

Birsa Munda died in:

1900

at a very young age.

Janjatiya Gaurav Divas

Birsa Munda's birth anniversary:

15 November

is observed in India as:

Janjatiya Gaurav Divas.

This commemorates the contributions of tribal freedom fighters and communities to India's history and development.

Thus, BIRSA 101 creates an important current-affairs connection between:

Biotechnology + Public Health + Tribal Affairs + Modern Indian History.

What Is Sickle Cell Disease?

Sickle Cell Disease is an:

inherited genetic blood disorder.

It affects:

haemoglobin

which is the oxygen-carrying protein present in red blood cells.

Normal red blood cells are generally:

flexible and disc-shaped.

In Sickle Cell Disease, abnormal haemoglobin can cause red blood cells to become:

rigid, sticky and sickle/crescent-shaped

under certain conditions.

What Is Haemoglobin?

Haemoglobin is a protein found inside:

Red Blood Cells (RBCs).

Its major function is to transport:

oxygen

from the lungs to tissues throughout the body.

Haemoglobin also contributes to the transport of carbon dioxide back towards the lungs.

A defect affecting haemoglobin can therefore have systemic consequences.

Genetic Basis of Sickle Cell Disease

Sickle Cell Disease is associated with variants in the:

HBB gene

which encodes the beta-globin component of haemoglobin.

The classic sickle-cell mutation leads to production of:

Haemoglobin S (HbS).

Under low-oxygen and other favourable conditions, HbS molecules can polymerise.

This alters the shape and mechanical properties of red blood cells.

Why Do RBCs Become Sickle-Shaped?

Normal red blood cells are flexible enough to move through very small blood vessels.

In Sickle Cell Disease, abnormal haemoglobin can form long structures inside RBCs under certain conditions.

The cells consequently become:

rigid and sickle-shaped.

These abnormal cells can obstruct small blood vessels.

This process can reduce blood supply to tissues.

Major Effects of Sickle Cell Disease

Sickle Cell Disease can cause:

Anaemia

Abnormal red blood cells can be destroyed much more rapidly than normal RBCs.

This produces:

chronic haemolytic anaemia.

Pain Crises

Sickled cells can obstruct small blood vessels.

This can cause episodes of severe pain known as:

vaso-occlusive crises.

Organ Damage

Repeated interruption of blood supply can damage organs over time.

Increased Infection Risk

Damage to the spleen can increase vulnerability to certain infections.

Stroke

Blocked blood vessels in the brain can increase stroke risk.

Acute Chest Syndrome

This is a potentially serious complication affecting the lungs.

Sickle Cell Disease Is Inherited

Sickle Cell Disease is:

not an infectious disease.

It cannot spread from one person to another through:

• touch,

• food,

• air,

• water or

• casual contact.

It is inherited genetically.

This distinction is very important for public-health awareness.

Sickle Cell Trait vs Sickle Cell Disease

Students should distinguish between:

Sickle Cell Trait

and:

Sickle Cell Disease.

A person with sickle-cell trait carries a relevant genetic variant but usually does not have the same severe clinical disease seen in individuals with Sickle Cell Disease.

This distinction is particularly important in:

screening and genetic counselling.

What Is CRISPR?

CRISPR stands for:

Clustered Regularly Interspaced Short Palindromic Repeats.

CRISPR-based systems were originally discovered as part of microbial defence mechanisms.

Scientists adapted them into powerful tools for:

Genome Editing.

What Is Genome Editing?

Genome editing involves making targeted changes in:

DNA.

Depending on the technology and therapeutic objective, researchers may seek to:

• disrupt a gene,

• modify a sequence,

• correct a harmful genetic variant or

• alter gene regulation.

CRISPR greatly expanded the possibilities for targeted genome modification.

How Does CRISPR-Cas Work?

A simplified CRISPR gene-editing system involves two major components:

Guide RNA

and:

Cas enzyme.

The Guide RNA helps identify the desired DNA target.

The Cas enzyme performs the molecular cutting/editing function.

A simplified sequence is:

Guide RNA identifies target → Cas enzyme reaches target → DNA is cut/modified → Cellular repair processes act → Desired genetic effect is produced

This is why CRISPR is sometimes compared with:

molecular scissors

although the actual biological process is considerably more complex.

CRISPR and Sickle Cell Disease

Sickle Cell Disease is particularly relevant to genome-editing research because its molecular basis is well understood.

A patient's own blood-forming stem cells can potentially be collected and genetically modified outside the body.

These modified cells can then be returned to the patient under carefully controlled therapeutic protocols.

This is called an:

ex vivo

approach.

“Ex vivo” means that cells are modified:

outside the patient's body

before being returned.

Why Target Blood-Forming Stem Cells?

Blood cells originate from:

Hematopoietic Stem Cells.

These stem cells can generate different types of blood cells.

If an appropriate population of a patient's own stem cells is successfully edited, those cells may subsequently produce healthier blood-cell populations.

This creates the possibility of a long-lasting therapeutic effect.

Foetal Haemoglobin

An important concept in modern Sickle Cell Disease gene therapy is:

Foetal Haemoglobin (HbF).

Foetal haemoglobin is the dominant form of haemoglobin before birth and during early infancy.

Higher levels of HbF can reduce sickling.

Some gene-editing strategies therefore attempt to increase HbF production rather than directly replacing the sickle mutation itself.

This is an important conceptual distinction:

Gene editing does not always mean directly correcting the original mutation.

It may instead modify a regulatory pathway to produce a therapeutic effect.

Why Indigenous Development Matters

Gene therapies are among the world's most expensive medical technologies.

The Government's BIRSA 101 announcement noted that some advanced treatments overseas can be priced at approximately:

₹20–25 crore.

Such costs place them far beyond the reach of most patients.

An indigenous platform could potentially reduce costs through:

• domestic research,

• local manufacturing,

• Indian intellectual property,

• scalable production,

• technology transfer and

• reduced dependence on imported therapeutic platforms.

Affordable Gene Therapy

Affordability is therefore a central objective of BIRSA 101.

The CSIR-IGIB–Serum Institute partnership aims to bridge the gap between:

Laboratory Innovation

and:

Large-Scale Clinical Translation.

The ultimate challenge is not merely to develop a scientifically successful therapy but to make advanced treatment:

Safe + Effective + Scalable + Affordable + Accessible.

Ministry of Tribal Affairs Support

An important fact added in official 2026 information is that the:

Ministry of Tribal Affairs

provided approximately:

₹3.75 crore

in financial assistance to the BIRSA 101 project.

This reinforces the connection between the project and efforts to improve healthcare outcomes among tribal communities affected by Sickle Cell Disease.

BIRSA 101 Workshop – May 2026

On:

14 May 2026

the Ministry of Tribal Affairs, CSIR and CSIR-IGIB organised a dedicated workshop on BIRSA 101 at:

CSIR-IGIB, New Delhi.

The workshop was held as part of:

Janjatiya Garima Utsav 2026.

The programme discussed the development of the indigenous gene-editing initiative and its relevance to tribal health.

Development Since 2017

During the May 2026 workshop, the technical presentation traced India's indigenous BIRSA 101/CRISPR development efforts back to:

2017.

This demonstrates that the November 2025 launch was the result of years of research rather than a single short-term project.

National Sickle Cell Anaemia Elimination Mission

India's wider national response includes the:

National Sickle Cell Anaemia Elimination Mission.

It was launched on:

1 July 2023

by the Prime Minister in:

Madhya Pradesh.

The mission aims to tackle Sickle Cell Disease through:

• screening,

• early identification,

• counselling,

• awareness,

• treatment linkages and

• coordinated public-health interventions.

Screening Target – 7 Crore People

The National Sickle Cell Anaemia Elimination Mission established an ambitious screening target of:

7 crore people

up to the age group covered by the mission in high-burden areas.

The initial programme identified:

278 affected districts

in tribal areas for focused intervention.

For examinations:

7 crore people → 278 districts

is an important combination.

Target Year – 2047

The national goal is associated with:

eliminating Sickle Cell Disease as a public-health problem by 2047.

The year is significant because:

2047 marks 100 years of India's Independence.

Thus:

National Sickle Cell Mission → 2047

is an important current-affairs fact.

Screening and Gene Therapy Are Different

Students should not confuse the National Sickle Cell Anaemia Elimination Mission with BIRSA 101.

The national mission is a broad:

public-health programme

involving screening, counselling, prevention and disease management.

BIRSA 101 is an:

advanced gene-editing therapeutic initiative.

Therefore:

National Mission → Population-Level Public Health

BIRSA 101 → Advanced Genomic Therapeutics

Both contribute to the broader goal but perform different roles.

2020 Nobel Prize and CRISPR

The:

2020 Nobel Prize in Chemistry

was awarded jointly to:

Emmanuelle Charpentier

and:

Jennifer A. Doudna

for the development of a method for genome editing.

Their work on:

CRISPR-Cas9

helped transform genome editing into a powerful and widely used scientific tool.

This is an extremely important static-science link for competitive examinations.

CRISPR – Applications Beyond Sickle Cell Disease

CRISPR research has potential applications across many fields, including:

• inherited genetic disorders,

• cancer research,

• infectious-disease research,

• diagnostics,

• agriculture,

• biotechnology and

• functional genomics.

However, therapeutic applications require careful assessment because unintended genomic changes could create serious risks.

Safety and Ethical Issues

Genome editing raises several scientific and ethical issues.

Important concerns include:

Off-Target Editing

Changes may occur at unintended genomic locations.

Long-Term Safety

Some effects may emerge only after long follow-up periods.

Access and Equity

Extremely expensive therapies may worsen healthcare inequality.

Informed Consent

Patients must understand potential risks and uncertainties.

Germline Editing

Changes made to reproductive cells or embryos raise particularly serious ethical questions because they could be inherited by future generations.

BIRSA 101 should therefore be understood in the context of tightly regulated therapeutic development.

Somatic vs Germline Gene Editing

This distinction is important.

Somatic Gene Editing

Changes are made to cells of an individual patient.

They are generally:

not inherited by future generations.

Germline Gene Editing

Changes involve:

• sperm,

• eggs,

• embryos or

• cells contributing to future generations.

Such changes could potentially be inherited.

Therapeutic development for diseases such as Sickle Cell Disease focuses on:

somatic-cell approaches

rather than heritable germline modification.

CSIR – Important Static Facts

CSIR stands for:

Council of Scientific and Industrial Research.

It is one of India's major publicly funded scientific and industrial research organisations.

Its laboratory network conducts research across fields including:

• biotechnology,

• chemistry,

• genomics,

• pharmaceuticals,

• aerospace,

• materials,

• environment and

• engineering.

CSIR-IGIB is one of its constituent institutes.

BIRSA 101 – Quick Revision Table

बिरसा 101 – सिकल सेल रोग के लिए भारत की पहली स्वदेशी CRISPR-आधारित जीन चिकित्सा

भारत ने 19 नवंबर 2025 को जीनोमिक चिकित्सा के क्षेत्र में एक महत्वपूर्ण उपलब्धि हासिल की, जब बिरसा 101 का शुभारंभ किया गया।

भारत सरकार ने इसे:

सिकल सेल रोग के लिए भारत की पहली स्वदेशी CRISPR-आधारित जीन चिकित्सा

के रूप में प्रस्तुत किया।

इसका विकास:

CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB)

में किया गया है।

इसका शुभारंभ केंद्रीय विज्ञान एवं प्रौद्योगिकी राज्य मंत्री (स्वतंत्र प्रभार):

डॉ. जितेंद्र सिंह

ने किया।

बिरसा 101 क्या है?

बिरसा 101 सिकल सेल रोग के लिए विकसित:

स्वदेशी जीन-संपादन आधारित चिकित्सीय पहल

है।

इसका उद्देश्य केवल रोग के लक्षणों को नियंत्रित करना नहीं बल्कि रोग के आनुवंशिक आधार से जुड़ी प्रक्रिया पर प्रभाव डालने वाली उन्नत चिकित्सा विकसित करना है।

यह भारत की उन्नत जैव-चिकित्सकीय अनुसंधान क्षमता का महत्वपूर्ण उदाहरण है।

इसका विकास किसने किया?

बिरसा 101 का विकास:

CSIR-IGIB

ने किया।

CSIR-IGIB का पूरा नाम है:

Council of Scientific and Industrial Research – Institute of Genomics and Integrative Biology.

यह दिल्ली में स्थित CSIR की प्रमुख अनुसंधान संस्थाओं में से एक है।

स्वदेशी enFnCas9 तकनीक

बिरसा 101 की सबसे महत्वपूर्ण वैज्ञानिक विशेषताओं में से एक इसका स्वदेशी:

Engineered FnCas9

जीन-संपादन मंच है।

इसे संक्षेप में:

enFnCas9

भी कहा जाता है।

इसका अर्थ है कि यह उपलब्धि केवल किसी विदेशी CRISPR प्रणाली के उपयोग तक सीमित नहीं है, बल्कि इसके पीछे भारत में विकसित जीन-संपादन प्रौद्योगिकी भी है।

Serum Institute की भूमिका

19 नवंबर 2025 को:

CSIR-IGIB

और:

Serum Institute of India Pvt. Ltd.

के बीच औपचारिक प्रौद्योगिकी हस्तांतरण और सहयोग समझौता किया गया।

इसका उद्देश्य इस प्रौद्योगिकी को प्रयोगशाला से आगे बढ़ाकर:

• नैदानिक विकास,

• नियामकीय प्रगति,

• बड़े पैमाने पर निर्माण और

• भविष्य के व्यावसायीकरण

की दिशा में ले जाना है।

एक महत्वपूर्ण सावधानी

बिरसा 101 का 19 नवंबर 2025 को शुभारंभ होने का अर्थ यह नहीं है कि उसी दिन से यह प्रत्येक रोगी के लिए सामान्य अस्पतालों में उपलब्ध स्वीकृत उपचार बन गया था।

जीन चिकित्सा के लिए आवश्यक होते हैं:

सुरक्षा परीक्षण → प्रभावशीलता परीक्षण → नैदानिक अध्ययन → नियामकीय समीक्षा → निर्माण क्षमता → चिकित्सकीय उपलब्धता

2026 की आधिकारिक जानकारी के अनुसार प्रौद्योगिकी को आगे के विकास, नियामकीय प्रगति, निर्माण और व्यावसायीकरण के लिए Serum Institute को लाइसेंस किया गया है।

इस अंतर को परीक्षा और लेख दोनों में स्पष्ट रखना चाहिए।

बिरसा नाम क्यों?

इस चिकित्सा का नाम महान जनजातीय स्वतंत्रता सेनानी:

भगवान बिरसा मुंडा

के सम्मान में रखा गया है।

उनका जन्म:

15 नवंबर 1875

को हुआ था।

2025 में उनकी:

150वीं जयंती

मनाई गई।

बिरसा 101 का शुभारंभ उनकी 150वीं जयंती के कुछ दिनों बाद हुआ।

सिकल सेल रोग क्या है?

सिकल सेल रोग एक:

आनुवंशिक रक्त विकार

है।

यह मुख्य रूप से:

हीमोग्लोबिन

को प्रभावित करता है।

हीमोग्लोबिन लाल रक्त कोशिकाओं में पाया जाने वाला प्रोटीन है, जिसका मुख्य कार्य शरीर के विभिन्न भागों तक ऑक्सीजन पहुँचाना है।

लाल रक्त कोशिकाओं का आकार क्यों बदलता है?

सिकल सेल रोग में असामान्य हीमोग्लोबिन के कारण कुछ परिस्थितियों में लाल रक्त कोशिकाएँ:

कठोर, चिपचिपी और हंसिया के आकार की

हो सकती हैं।

सामान्य लाल रक्त कोशिकाएँ लचीली होती हैं और छोटी रक्त वाहिकाओं से आसानी से गुजर सकती हैं।

हंसिया के आकार की कठोर कोशिकाएँ छोटी रक्त वाहिकाओं में फँस सकती हैं।

इससे ऊतकों तक रक्त और ऑक्सीजन की आपूर्ति बाधित हो सकती है।

रोग के प्रमुख प्रभाव

सिकल सेल रोग से:

रक्ताल्पता

लाल रक्त कोशिकाओं के तेजी से नष्ट होने के कारण हो सकती है।

तीव्र दर्द

रक्त वाहिकाओं में अवरोध के कारण हो सकता है।

अंगों को क्षति

बार-बार रक्त प्रवाह बाधित होने से हो सकती है।

इसके अतिरिक्त संक्रमण, फेफड़ों की गंभीर समस्या और आघात जैसी जटिलताएँ भी हो सकती हैं।

यह संक्रामक रोग नहीं है

सिकल सेल रोग:

संक्रामक रोग नहीं है।

यह छूने, भोजन, पानी या हवा के माध्यम से एक व्यक्ति से दूसरे व्यक्ति में नहीं फैलता।

यह:

आनुवंशिक रूप से विरासत में मिलने वाला रोग

है।

CRISPR क्या है?

CRISPR का विस्तृत रूप है:

Clustered Regularly Interspaced Short Palindromic Repeats.

यह आधुनिक:

Genome Editing

की अत्यंत महत्वपूर्ण तकनीक है।

इसकी सहायता से वैज्ञानिक DNA के विशिष्ट स्थानों को लक्षित कर परिवर्तन कर सकते हैं।

CRISPR कैसे काम करता है?

सरल रूप में CRISPR प्रणाली में:

Guide RNA

लक्षित DNA अनुक्रम की पहचान करने में सहायता करता है।

इसके बाद:

Cas enzyme

उस लक्षित स्थान पर कार्य करता है।

सरल क्रम:

लक्षित DNA की पहचान → Cas enzyme का पहुँचना → DNA में लक्षित परिवर्तन → कोशिका की मरम्मत प्रक्रिया → इच्छित आनुवंशिक प्रभाव

इसी कारण CRISPR को कभी-कभी आणविक कैंची की उपमा दी जाती है।

Sickle Cell और Gene Editing

सिकल सेल रोग का आनुवंशिक आधार अच्छी तरह ज्ञात है।

आधुनिक जीन चिकित्सा में रोगी की:

रक्त बनाने वाली Stem Cells

को शरीर से बाहर निकालकर उनमें जीन-संपादन किया जा सकता है।

बाद में संशोधित कोशिकाएँ रोगी के शरीर में वापस दी जा सकती हैं।

इसे:

Ex Vivo Gene Editing

कहा जाता है।

Foetal Haemoglobin का महत्व

सिकल सेल रोग की कुछ आधुनिक जीन-संपादन रणनीतियाँ:

Foetal Haemoglobin (HbF)

का स्तर बढ़ाने का प्रयास करती हैं।

HbF की अधिक मात्रा लाल रक्त कोशिकाओं के sickling को कम करने में सहायक हो सकती है।

इसलिए यह समझना महत्वपूर्ण है कि जीन-संपादन हमेशा मूल रोगजनक mutation को सीधे बदलने तक सीमित नहीं होता।

कभी-कभी किसी दूसरे आनुवंशिक नियंत्रण तंत्र को बदलकर चिकित्सीय प्रभाव प्राप्त किया जाता है।

स्वदेशी विकास क्यों महत्वपूर्ण है?

अंतरराष्ट्रीय स्तर पर कुछ अत्याधुनिक जीन चिकित्साएँ अत्यंत महँगी हैं।

BIRSA 101 की घोषणा के समय सरकार ने विदेशी उपचारों की लागत लगभग:

₹20–25 करोड़

तक होने का उल्लेख किया।

भारत में स्वदेशी तकनीक विकसित करने से भविष्य में:

• लागत कम करने,

• स्थानीय निर्माण बढ़ाने,

• आयात पर निर्भरता घटाने,

• बड़े स्तर पर उत्पादन करने और

• अधिक रोगियों तक उपचार पहुँचाने

की संभावना बढ़ सकती है।

Ministry of Tribal Affairs का योगदान

2026 की आधिकारिक जानकारी के अनुसार:

Ministry of Tribal Affairs

ने BIRSA 101 परियोजना को लगभग:

₹3.75 करोड़

की वित्तीय सहायता प्रदान की।

यह विशेष रूप से महत्वपूर्ण है क्योंकि भारत के कई जनजातीय क्षेत्रों में सिकल सेल रोग का बोझ अधिक है।

National Sickle Cell Anaemia Elimination Mission

भारत सरकार ने:

1 जुलाई 2023

को:

National Sickle Cell Anaemia Elimination Mission

शुरू किया।

इसका शुभारंभ:

मध्य प्रदेश

से किया गया।

इसका उद्देश्य बड़े पैमाने पर:

• Screening,

• Early Detection,

• Counselling,

• Awareness और

• Disease Management

को मजबूत करना है।

7 करोड़ लोगों की Screening

राष्ट्रीय मिशन के अंतर्गत:

7 करोड़ लोगों

की जाँच का लक्ष्य रखा गया।

प्रारंभिक कार्यक्रम में:

278 प्रभावित जिलों

पर विशेष ध्यान दिया गया।

इसलिए परीक्षा के लिए याद रखें:

7 Crore → 278 Districts

2047 का लक्ष्य

भारत का दीर्घकालीन लक्ष्य:

2047 तक Sickle Cell Disease को एक प्रमुख सार्वजनिक स्वास्थ्य समस्या के रूप में समाप्त करना

है।

2047 भारत की स्वतंत्रता के:

100 वर्ष

पूरे होने का वर्ष है।

National Mission और BIRSA 101 में अंतर

दोनों को एक ही कार्यक्रम नहीं समझना चाहिए।

National Sickle Cell Anaemia Elimination Mission

एक व्यापक सार्वजनिक स्वास्थ्य कार्यक्रम है।

इसके अंतर्गत:

• Screening,

• Counselling,

• Awareness और

• Disease Management

जैसे उपाय आते हैं।

इसके विपरीत:

BIRSA 101

एक उन्नत:

Gene-Editing Therapeutic Initiative

है।

2020 Nobel Prize

2020 का Nobel Prize in Chemistry

संयुक्त रूप से:

Emmanuelle Charpentier

और:

Jennifer A. Doudna

को दिया गया था।

उन्हें:

Genome Editing की विधि विकसित करने

के लिए सम्मानित किया गया।

उनका CRISPR-Cas9 संबंधी कार्य आधुनिक जीन-संपादन विज्ञान की सबसे महत्वपूर्ण उपलब्धियों में से एक है।

परीक्षा के लिए महत्वपूर्ण तथ्य

1. Name: BIRSA 101

2. Disease: Sickle Cell Disease

3. Technology: CRISPR-based Gene Editing

4. Developer: CSIR-IGIB

5. Indigenous Platform: Engineered FnCas9

6. Launch: 19 November 2025

7. Launched By: Dr. Jitendra Singh

8. Named After: Bhagwan Birsa Munda

9. Birsa Munda Birth: 15 November 1875

10. Technology Partner: Serum Institute of India

11. Tribal Affairs Funding: Approx. ₹3.75 crore

12. Disease Type: Inherited Blood Disorder

13. Main Protein Affected: Haemoglobin

14. Important Gene: HBB

15. Abnormal Haemoglobin: HbS

16. CRISPR: Genome Editing Technology

17. National Mission Launch: 1 July 2023

18. Launch State: Madhya Pradesh

19. Screening Target: 7 crore people

20. Focused Districts: 278

21. Elimination Goal: 2047

22. CRISPR Nobel: Chemistry, 2020

23. Nobel Laureates: Emmanuelle Charpentier and Jennifer Doudna

Frequently Asked Questions

What is BIRSA 101?

It is India's first indigenous CRISPR-based gene-editing therapy/programme for Sickle Cell Disease.

Who developed BIRSA 101?

CSIR-Institute of Genomics and Integrative Biology.

When was it launched?

19 November 2025.

Who launched it?

Dr. Jitendra Singh.

Which technology does it use?

An indigenous CRISPR-based engineered FnCas9 platform.

After whom is BIRSA 101 named?

Bhagwan Birsa Munda.

Which company received the technology for further development?

Serum Institute of India Pvt. Ltd.

Does the 2025 launch mean it was immediately available as routine treatment?

No. Further clinical translation, regulatory advancement, manufacturing and commercialisation processes are required.

What is Sickle Cell Disease?

An inherited blood disorder involving abnormal haemoglobin and sickling of red blood cells.

When was India's National Sickle Cell Anaemia Elimination Mission launched?

1 July 2023.

What is the national target year?

2047.

What is the screening target?

7 crore people.

How many affected districts were initially targeted?

278 districts.

Quick Revision

BIRSA 101 → 19 November 2025 → India's First Indigenous CRISPR-Based Sickle Cell Gene Therapy → CSIR-IGIB → enFnCas9 → Serum Institute → Birsa Munda → Tribal Health → Sickle Cell Disease → HBB/HbS → National Mission 1 July 2023 → 7 Crore Screening → 278 Districts → 2047 Goal

Conclusion

BIRSA 101 represents an important milestone in India's development of indigenous genomic medicine.

Developed at CSIR-IGIB using an indigenous engineered FnCas9 gene-editing platform, the initiative seeks to create an affordable therapeutic pathway for Sickle Cell Disease, a hereditary blood disorder that imposes a particularly high burden on several tribal communities.

The technology-transfer partnership with Serum Institute of India is intended to move the innovation from research towards clinical translation, regulatory advancement, scalable manufacturing and eventual commercialisation.

At the same time, BIRSA 101 complements India's broader National Sickle Cell Anaemia Elimination Mission, which focuses on population-level screening, counselling and disease management.

For examinations, remember:

BIRSA 101 → CRISPR → CSIR-IGIB → Sickle Cell Disease → Birsa Munda → Serum Institute → 19 November 2025 → 2047 Sickle Cell Elimination Goal.